Financial Results for the First Nine Months of Fiscal Year Ending December 2017

I	Summary	Information	P.1
	1	Financial Results	P.1
	2	Financial Conditions	P.1
Π	Financial F	Results for the First Nine Months of FY2017	P.2
	1	Statement of Income	P.2
	2	Sales of Products	P.4
	3	Balance Sheet	P.5
	4	Capital Expenditures	P.5
	5	Depreciation/Amortization	P.6
	6	Research and Development	P.6
Ш	Financial F	Forecasts for the FY2017	P.7
	1	Statement of Income	P.7
	2	Sales of Products	P.9
	3	Capital Expenditures	P.10
	4	Depreciation/Amortization	P.10
	5	Dividends	P.10
【In	nportant no	tes on forward-looking statements】	P.10

% This material is prepared based on Japan GAAP.

times Amounts are rounded down to the nearest million yen.

October 26, 2017




I Summary Information ① Financial Results


The forecasts for the FY2017 have been changed from the previous forecasts announced at the first six months of FY2017 financial results announcement on July 27, 2017.

(Millions of Yen)	FY2016 First nine mon <i>A</i>	ths	FY2017 First nine months <i>B</i>	Change _{B-A}	Change (%) (B-A)/A	FY2016 Full year	FY2017 revised forecast C	Progress ratio (%) <i>B/C</i>
Net sales	43,7	768	45,726	1,957	4.5	60,206	63,100	72.5
Operating income	2,5	574	3,660	1,085	42.2	3,819	5,000	73.2
Ordinary income	2,7	/13	3,735	1,021	37.6	3,999	5,100	73.2
Net income	1,7	755	2,771	1,016	57.9	2,839	3,800	72.9
(Reference)								
R&D expenses	3,5	577	3,516	(60)	(1.7)	4,654	4,880	72.1
Earnings per share (EPS)	(¥) 62	.04	98.83	36.79		100.41	135.48	
Return on equity (ROE)	(%)	2.1	3.3	1.2		3.4	-	
Ratio of ordinary income to total assets	(%)	2.8	3.8	1.0		4.1	-	
Ratio of operating income to net sales	(%)	5.9	8.0	2.1		6.3	_	
Return on assets (ROA)	(%)	1.8	2.8	1.0		2.9	_	









② Financial Conditions

(Millions of Yen)		December 31, 2016 <i>A</i>	September 30, 2017 <i>B</i>	Change _{B-A}	Change (%) <i>(B-A)/A</i>
Total assets		98,525	100,362	1,837	1.9
Total equity		83,556	85,025	1,468	1.8
Equity ratio	(%)	84.8	84.7	(0.1)	
Book value per share (BPS)	(¥)	2,978.80	3,031.04	52.24	

I Financial Results for the First Nine Months of FY2017

① Statement of Income


	FY2016	FY2017	Change	Change
(Millions of Yen)	First nine months	First nine months	Change	(%)
	A	В	B-A	(B-A)/A
Net sales	43,768	45,726	1,957	4.5
Sales of products	43,329	44,930	1,600	3.7
Renal disease and hemodialysis	18,226	17,995	(230)	(1.3)
Skin disease	7,321	7,235	(86)	(1.2)
Allergens	982	1,437	455	46.4
HIV infection	12,435	14,043	1,607	12.9
Other	4,364	4,218	(145)	(3.3)
Other sales	439	795	356	81.2
Cost of sales	21,857	22,602	745	3.4
Cost of products sold	21,807	22,561	754	3.5
Other cost	49	40	(9)	(18.8)
Gross profit	21,911	23,123	1,211	5.5
Selling, general and	19,337	19,463	126	0.7
administrative expenses	19,557	19,405	120	0.7
R&D expenses	3,577	3,516	(60)	(1.7)
Others	15,759	15,946	186	1.2
Operating income	2,574	3,660	1,085	42.2
Non-operating income	140	86	(53)	_
Non-operating expenses	1	12	10	_
Ordinary income	2,713	3,735	1,021	37.6
Extraordinary loss	17	20	3	_
Income before income taxes	2,696	3,714	1,017	37.7
Income taxes	941	942	1	_
Net income	1,755	2,771	1,016	57.9

(Reference) Ratio to net sales


(%)	FY2016 First nine months	FY2017 First nine months B	Change <i>B-A</i>
Cost of sales	49.9	49.4	(0.5)
SG&A	44.2	42.6	(1.6)
R&D expenses	8.2	7.7	(0.5)
Operating income	5.9	8.0	2.1
Ordinary income	6.2	8.2	2.0
Net income	4.0	6.1	2.1

[Factors in increase/decrease compared with the same term of the last fiscal year]

Net Sales (¥45,726 million : Increase ¥1,957 million year-on-year)



Operating income (¥3,660 million : Increase ¥1,085 million year-on-year)



Ordinary income (¥3,735 million : Increase ¥1,021 million year-on-year)

Special remarks: None

Net income (¥2,771 million : Increase ¥1,016 million year-on-year)

Special remarks: None

Sales of Products

) Sales of Products	FY2016	FY2017	Chapter	Change
<i>fillions of Yen)</i> F	First nine months	First nine months	Change	(%) (P_A)(A
ales of Products	<u> </u>	<u>в</u> 44,930	<u>В-А</u> 1,600	(<i>B-A)/A</i> 3.7
REMITCH	9,921	9,828	(93)	(0.9)
Oral anti-pruritus agent [Renal disease and hemodialysis]				
Descovy 3 Antiviral agent for HIV [HIV infection]	_	6,035	6,035	-
ANTEBATE ×1 Topical corticosteroid	4,625	4,559	(65)	(1.4)
[Skin disease] Riona	4,021	4,438	417	10.4
Agent for hyperphosphatemia [Renal disease and hemodialysis]	7,021	7,730	417	10.4
Genvoya X2 Antiviral agent for HIV [HIV infection]	669	4,410	3,740	558.6
Truvada Antiviral agent for HIV [HIV infection]	9,351	3,372	(5,979)	(63.9)
BIO-THREE Viable bacterial preparations [Other]	1,765	1,824	59	3.4
KAYEXALATE ×1 Agent for hyperkalemia [Renal disease and hemodialysis]	1,605	1,540	(64)	(4.0)
FUTHAN X1 Protease inhibitor [Renal disease and hemodialysis]	1,762	1,435	(326)	(18.5)
ZEFNART Topical antifungal agent [Skin disease]	993	1,107	114	11.5
LOCOID ×1 Topical corticosteroid [Skin disease]	1,011	1,030	18	1.8
CEDARTOLEN ×1 Japanese cedar pollinosis (Allergen Immunothe [Allergens]	620 rapy)	883	263	42.4
Magsent Tocolysis in threatened premature labor Eclampsia-suppressing and treatment [Other]	822	789	(33)	(4.0)
URINORM X1 Uricosuric agent [Renal disease and hemodialysis]	915	752	(163)	(17.8)
Stribild Antiviral agent for HIV	2,239	120	(2,118)	(94.6)
[HIV infection] Others	3,003	2,802	(201)	(6.7)

%1 In-house products

X2 Launched in July 2016

X3 Launched in January 2017

(References) Sales and ratio of in-house products

(Millions of Yen)	FY2016 First nine months	FY2017 First nine months	Change	Change (%)
	А	В	B-A	(B-A)/A
Sales of in-house products	11,897	11,659	(237)	(2.0)
Ratio of in-house (%) product sales	27.5	26.0	(1.5)	_

3 Balance Sheet

(Millions of Yen)	December 31, 2016	September 30, 2017	Change	Change (%)	Component ratio (%)
	А	В	B-A	(B-A)/A	(September 30, 2017)
Current assets	80,123	81,533	1,409	1.8	81.2
Cash and deposits	22,393	17,196	(5,197)		
Deposits in the cash	7,091	5,076	(2,015)		
management system	7,001	5,676	(2,013)		
Notes and accounts	26,560	26,321	(239)		
receivable-trade	20,500	20,521	(239)		
Short-term	11,102	20,102	9,000		
investment securities	11,102	20,102	9,000		
Inventories	10,606	10,395	(211)		
Others	2,368	2,441	73		
Noncurrent assets	18,401	18,828	427	2.3	18.8
Property, plant and equipment	5,752	5,551	(200)		
Intangible assets	896	820	(76)		
Investments and other assets	11,752	12,456	704		
Investment securities	3,877	5,178	1,301		
Long-term prepaid expenses	6,486	5,914	(571)		
Others	1,389	1,363	(25)		
Total assets	98,525	100,362	1,837	1.9	100.0
Current liabilities	13,310	13,642	332	2.5	13.6
Accounts payable-trade	6,698	7,824	1,125		
Accounts payable-other	3,178	2,351	(826)		
Income taxes payable	767	446	(320)		
Accrued employees' bonuses	676	1,359	683		
Others	1,990	1,660	(330)		
Long-term liabilities	1,658	1,694	36	2.2	1.7
Total liabilities	14,969	15,337	368	2.5	15.3
Shareholders' equity	82,993	84,418	1,425	1.7	84.1
Unrealized gain on	558	598	39	7.1	0.6
available-for-sale securities	558	598	39	7.1	0.6
Subscription rights to shares	4	8	3	88.6	0.0
Total equity	83,556	85,025	1,468	1.8	84.7
Total liabilities and equity	98,525	100,362	1,837	1.9	100.0
Major factors in increase/decrease (Current assets) Short-term investment securities (Noncurrent assets)	se with acquisition c	f debt securities, m	oney trust and c	ertificates of d	eposit

Investment securities	:	Increase with acquisition of debt securities
		Decrease with transfer to short-term investment securities
Long-term prepaid expenses	:	Decrease with amortization of marketing rights
(Current liabilities)		
Accounts payable-trade	:	Increase with increase in purchasing products

④ Capital Expenditures

(Millions of Yen)	FY2016 First nine months <i>A</i>	FY2017 First nine months <i>B</i>	Change <i>B-A</i>	Change (%) (<i>B-A)/A</i>
Capital expenditures	601	650	48	8.1
PP&E	420	506	86	20.5
Intangible assets	181	144	(37)	(20.5)

Descriptions of capital expenditures

PP&E	: Investment mainly in manufacturing facilities aiming to maintain and improve productivity
Intangible assets	: Investment in software aiming to streamline operations

5 Depreciation/Amortization

(Millions of Yen)	FY2016 First nine months A	FY2017 First nine months B	Change <i>B-A</i>	Change (%) (B-A)/A
Depreciation and amortization of intangible assets	1,000	889	(110)	(11.1)
Amortization of long-term prepaid expenses	759	793	34	4.5

6 Research and Development

Development		Formulation/ Development stage (domestic)						
code [Product Name]	Indication	Route of administration	Phase I	Phase II	PhaseⅢ	Application	Approval	Remarks
Renal disease and	hemodialysis							
JTT-751 [Riona® Tablets]	Iron-deficiency anemia	Oral		Phase II				•Licensing agreement signed with Keryx for development and commercialization of hyperphosphatemia drug in Japan •Co-development with JT(Additional indication) •Riona filed by JT has been approved as a treatment of hyperphosphatemia in January 2014, and is being promoted and distributed by Torii.
Skin disease								
JTE-052	Atopic dermatitis	Topical			PhaseⅢ			• JT's original compound • Licensing agreement signed with JT for development and commercialization
	Atopic dermatitis in children	Topical		Phase II				• JT's original compound • Licensing agreement signed with JT for development and commercialization
Allergens								
TO-203 ſMITICURE® House Dust Mite	House dust mite induced allergic asthma (Allergen Immunotherapy)	Sublingual tablet		Phase (Study cor				 Licensing agreement signed with ALK for providing exclusive development and sales rights in Japan In-house Examining the future development policy
Sublingual TabletsJ	House dust mite induced allergic rhinitis in children (Allergen Immunotherapy)	Sublingual tablet				Application		 Licensing agreement signed with ALK for providing exclusive development and sales rights in Japan In-house NDA filing by Torii in March 2017
TO-206 「CEDARCURE® Japanese Cedar Pollen Sublingual Tablets」	Japanese cedar pollinosis (Allergen Immunotherapy)	Sublingual tablet					Approval	 ·In-house ·NDA approval obtained by Torii in September 2017

Updates since the previous announcement on July 27, 2017

Manufacturing and marketing approval of TO-206(CEDARCURE® Japanese Cedar Pollen Sublingual Tablets) for the indication of Japanese cedar pollinosis by Torii

Additional Information

•In August 2016, $\overline{\text{JT}}$ and Torii signed an exclusive license agreement with Menlo Therapeutics Inc. for the development and commercialization of serlopitant, oral neurokinin (NK-1) receptor antagonist, in Japan. (JT and Torii will jointly develop serlopitant.)

•In October 2017, Torii signed an exclusive license agreement with JT for co-development and commercialization of JT's original compound, JTZ-951, a new experimental hypoxia inducible factor - prolyl hydroxylase domain containing protein (HIF-PH) inhibitor in Japan. JTZ-951 is developed by JT for the treatment of anemia associated with chronic kidney disease. (JT and Torii will jointly develop JTZ-951.)

(Reference)

In October 2017, JT announced that the company signed an exclusive license agreement with EirGen Pharma Limited for the development and commercialization in Japan of calcifediol extended-release capsules (marketed by OPKO Health, Inc. in the U.S. under the brand name "RAYALDEE®") for the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease, and Torii is expected to commercialize the product once it is approved.

Ⅲ Financial Forecasts for the FY2017

The forecasts for the FY2017 have been changed from the previous forecasts announced at the first six months of FY2017 financial results announcement on July 27, 2017.

① Statement of Income


(Millions of Yen)	FY2017 previous forecast <i>A</i>	FY2017 revised forecast <i>B</i>	Change _{B-A}	FY2016 c	Change ^{B-C}	Change (%) (B-C)/C
Net sales	63,100	63,100	_	60,206	2,893	4.8
Sales of products	62,100	62,080	(20)	59,620	2,459	4.1
Renal disease and hemodialysis	25,260	24,840	(420)	25,141	(301)	(1.2)
Skin disease	9,600	9,640	40	9,811	(171)	(1.8)
Allergens	2,000	2,070	70	1,485	584	39.3
HIV infection	19,410	19,700	290	17,225	2,474	14.4
Other	5,830	5,830	-	5,956	(126)	(2.1)
Other sales	1,000	1,020	20	586	433	74.0
Cost of sales	30,800	30,900	100	30,287	612	2.0
Gross profit	32,300	32,200	(100)	29,919	2,280	7.6
SG&A	27,000	27,200	200	26,099	1,100	4.2
R&D expenses	4,670	4,880	210	4,654	225	4.9
Others	22,330	22,320	(10)	21,445	874	4.1
Operating income	5,300	5,000	(300)	3,819	1,180	30.9
Ordinary income	5,400	5,100	(300)	3,999	1,100	27.5
Net income	3,900	3,800	(100)	2,839	960	33.8

(Reference) Ratio to net sales


(%)	FY2017 previous forecast	FY2017 revised forecast	Change	FY2016	Change
	A	В	B-A	С	B-C
Cost of sales	48.8	49.0	0.2	50.3	(1.3)
SG&A	42.8	43.1	0.3	43.4	(0.3)
R&D expenses	7.4	7.7	0.3	7.7	0.0
Operating income	8.4	7.9	(0.5)	6.3	1.6
Ordinary income	8.6	8.1	(0.5)	6.6	1.5
Net income	6.2	6.0	(0.2)	4.7	1.3

[Factors in increase/decrease compared with the previous forecast for the FY2017]

Net sales (¥63,100 million : No modification)



Operating income (¥5,000 million : Decrease ¥300 million)



Ordinary income (¥5,100 million : Decrease ¥300 million)

Special remarks: None

Net income (¥3,800 million : Decrease ¥100 million)

Special remarks: None

② Sales of Products

illions of Yen)	FY2017 previous forecast	FY2017 revised forecast	Change	FY2016	Change	Change (%)
	A previous forecast	B	B-A	С	B-C	(%) (B-C)/C
les of Products	62,100	62,080	(20)	59,620	2,459	4.
REMITCH	13,950	13,450	(500)	13,645	(195)	(1.
Oral anti-pruritus agent [Renal disease and hemodialysis]						
Descovy X3 Antiviral agent for HIV [HIV infection]	8,980	9,560	580	_	9,560	
Riona	6,240	6,310	70	5,634	675	12
Agent for hyperphosphatemia [Renal disease and hemodialysis]						
ANTEBATE ×1 Topical corticosteroid [Skin disease]	6,200	6,200	_	6,277	(77)	(1
Genvoya X2 Antiviral agent for HIV [HIV infection]	5,830	6,020	190	1,865	4,154	222
Truvada Antiviral agent for HIV [HIV infection]	4,280	3,830	(450)	12,754	(8,924)	(70
BIO-THREE	2,460	2,510	50	2,455	54	2
Viable bacterial preparations [Other]	,	,		,		
KAYEXALATE ×1 Agent for hyperkalemia	2,090	2,100	10	2,178	(78)	(3
[Renal disease and hemodialysis] FUTHAN X1 Protease inhibitor [Renal disease and hemodialysis]	1,980	1,980	_	2,462	(482)	(19
LOCOID ×1	1,380	1,380	_	1,352	27	2
Topical corticosteroid [Skin disease]	,	,		,		
ZEFNART Topical antifungal agent [Skin disease]	1,300	1,340	40	1,275	64	5
CEDARTOLEN <u>%1</u>	1,200	1,220	20	937	282	30
Japanese cedar pollinosis (Allergen Immunotl [Allergens]	herapy)					
Magsent Tocolysis in threatened premature labor Eclampsia-suppressing and treatment [Other]	1,150	1,120	(30)	1,165	(45)	(3
URINORM ×1	1,000	1,000	_	1,219	(219)	(18
Uricosuric agent [Renal disease and hemodialysis]	,			,	. /	、 -
Stribild Antiviral agent for HIV [HIV infection]	140	130	(10)	2,371	(2,241)	(94
Others	3,920	3,930	10	4,023	(93)	(2

***3** Launched in January 2017

(References)	Sales and	ratio of i	n-house	products

(References) sales and ra		iouse produces						
(Millions of Yen)	illions of Yen)		FY2017 revised forecast	Change	FY2016	Change	Change (%)	
		А	В	B-A	С	B-C	(B-C)/C	
Sales of in-house products		16,000	16,050	50	16,316	(266)	(1.6)	
Ratio of in-house product sales	(%)	25.8	25.9	0.1	27.4	(1.5)	_	

③ Capital Expenditures

(Millions of Yen)	FY2017 previous forecast	FY2017 revised forecast	Change	FY2016	Change	Change (%)
	А	В	B-A	С	B-C	(B-C)/C
Capital expenditures	1,257	1,078	(179)	891	186	20.9
PP&E	959	801	(158)	644	156	24.2
Intangible assets	298	277	(21)	246	30	12.1

_		
	Descriptions of capita	l expenditures
	PP&E	: Investment mainly in manufacturing facilities aiming to maintain and improve productivity
	Intangible assets	: Investment in software aiming to streamline operations

④ Depreciation/Amortization

(Millions of Yen)	FY2017 previous forecast <i>A</i>	FY2017 revised forecast <i>B</i>	Change <i>B-A</i>	FY2016 C	Change <i>B-C</i>	Change (%) (B-C)/C
Depreciation and amortization of intangible assets	1,180	1,175	(5)	1,339	(164)	(12.3)
Amortization of long-term prepaid expenses	1,059	1,062	3	1,018	43	4.2

⑤ Dividends

		FY2017 previous forecast <i>A</i>	FY2017 revised forecast <i>B</i>	Change <i>B-A</i>	FY2016 C	Change <i>B-C</i>	Change (%) <i>(B-C)/C</i>
Dividends per share	(¥)	48	48	0	48	0	0.0
Dividends payout ratio	(%)	34.5	35.4	0.9	47.8	(12.4)	_

[Important notes on forward-looking statements]

The forecasts presented in this material are forward-looking statements. Reflecting assumptions based on information available on the date of publication, these statements are subject to inherent risks and uncertainties. Accordingly, unforeseen factors may cause actual results to differ materially from the projections contained herein.

Torii will not necessarily revise this material regardless of any new information, future events or other results. At the present moment, the following matters may be pointed out as risks or uncertain factors that could affect the Company's future results (but such risks or uncertain factors are not limited to these):

- \diamond Changes in Pharmaceutical and Medical Device Law, Other Acts or Regulations
- \diamondsuit Delay or Discontinuance of Research and Development
- \Diamond Drug Price Listing and Revisions
- \diamond Adverse Drug Reactions
- \diamond Stoppage of Product Supply and Product Recall
- \diamondsuit Litigation Risk